Home Data Calendar Blog

FGEN

Tables

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Common Stock Value 0.980.980.970.940.940.940.930.930.930.930.920.910.910.900.890.880.870.870.860.850.850.840.830.820.820.710.640.640.630.630.620.620.610.600.590.59NANANA
dei: Entity Common Stock Shares Outstanding NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Weighted Average Number Of Diluted Shares Outstanding 98.2597.7394.69NA93.7793.4793.04NA92.8192.28NANA93.6889.45NANA87.0191.73NANA84.5183.75NANANA69.64NANANA69.02NANANA68.75NANANA37.11NA
Weighted Average Number Of Shares Outstanding Basic 98.2597.7394.69NA93.7793.4793.04NA92.6492.28NANA90.5689.45NANA87.0186.44NANA84.5183.75NANANA69.64NANANA62.58NANANA59.80NANANA13.35NA
Weighted Average Number Of Share Outstanding Basic And Diluted NANANANANANA93.04NANA92.2891.69NANA89.4588.22NANANA85.70NA84.5183.7582.86NA75.8969.6464.04NA62.86NA62.18NA60.77NA59.20NA13.50NA13.21
Earnings Per Share Basic -0.65-0.90-0.81-0.71-0.98-0.78-0.68-1.450.54-1.45NA-0.650.36-0.95NANA-0.571.34NANA-0.50-0.28NANANA-0.48NANANA0.39NANANA0.95NANANA1.36NA
Earnings Per Share Diluted -0.65-0.90-0.81-0.71-0.98-0.78-0.68-1.450.54-1.45NA-0.650.35-0.95NANA-0.571.26NANA-0.50-0.28NANANA-0.48NANANA0.35NANANA0.83NANANA0.58NA
Earnings Per Share Basic And Diluted NANANANANANA-0.68NANA-1.45-0.78NANA-0.95-0.89NANANA-0.530.25-0.50-0.28-0.50-0.24-0.50-0.46-0.52-0.54-0.38NA-0.45-0.85-0.74NA-0.78-2.50-2.93NA-1.23

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Revenue From Contract With Customer Excluding Assessed Tax 40.1344.3236.1634.3715.7329.8160.8316.54155.9724.3638.4365.0044.0342.8924.407.9733.17191.5723.86108.0629.0343.9531.9330.7440.5530.2726.8935.5230.1089.2828.2824.4419.54120.5516.3016.1113.6689.9617.88
Revenues 40.1344.3236.1634.3715.7329.8160.8316.54155.9724.3638.4365.0044.0342.8924.407.9733.17191.5723.86108.0629.0343.9531.9342.5127.2729.0026.8931.9130.1089.2828.2824.4419.54120.5516.3016.1113.6689.9617.88
Cost Of Revenue 4.245.713.494.924.316.814.243.123.273.083.402.622.21NANANANANANANANANANANANANANANANANANANANANANANANANANA
Costs And Expenses 103.62132.37112.25100.52109.39108.03123.82151.78105.00158.20108.86123.0011.70NANANANANANANANANANANANANANANANANANANANANANANANANANA
Research And Development Expense 61.1995.4874.4961.6375.1870.9689.02113.9275.88122.5774.6878.1358.4861.4154.9056.8049.9652.0150.5070.2856.4452.1456.9752.4750.3446.9846.7350.6140.5652.3943.6559.9252.0751.5550.5451.2640.6233.2725.65
General And Administrative Expense NANANANA29.90NANANA25.85NANANANANANANANANANA17.8515.3615.0515.5513.8512.9513.4311.5312.5911.6510.3811.4212.9611.249.6810.4812.8210.147.526.43
Selling General And Administrative Expense 25.5731.1834.2733.9729.9030.2630.5634.7425.8532.5530.7842.25-48.9863.5349.6050.7135.8226.7422.2117.8515.3615.0515.55NANANANANANANANANANANANANANANANA
Operating Income Loss -63.48-88.05-76.09-66.15-93.66-78.22-62.99-135.2450.97-133.84-70.43-58.0032.33-85.14-81.07-100.44-52.85112.82-48.8419.92-42.77-23.24-40.60-23.81-36.02-31.41-31.37-31.28-22.1026.51-26.79-48.45-43.7759.31-44.72-47.97-37.0949.17-14.21
Interest Expense 5.023.072.371.120.080.140.100.110.110.350.500.540.580.650.630.670.700.740.772.732.742.752.771.802.772.762.382.752.762.442.782.752.762.762.762.932.722.732.73
Interest Expense Debt 2.901.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Interest Income Expense Nonoperating Net -0.73-0.42-1.34-0.201.715.06-0.420.93-1.41-0.72-0.95-0.470.89-0.012.532.383.493.393.411.040.34-0.10-0.701.84-1.66-1.73-1.73-2.53-1.89-2.31-1.36-2.64-1.30-2.06-1.92NANANANA
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments -64.21-88.47-77.43-66.35-91.94-73.17-63.41-134.3149.56-134.55-71.38-58.2733.23NANANANANANANANANANANANANANANANANANANANA57.26-46.64NANA46.83-16.24
Income Tax Expense Benefit 0.08-0.230.070.110.110.020.110.110.11-0.000.130.170.210.17-0.190.070.080.20-0.030.010.120.070.100.150.060.050.060.190.16-0.11-0.300.280.030.20-0.270.000.000.000.00
Profit Loss -63.62-87.68-76.70-66.17-91.65-72.62-63.20-134.0849.80-133.99-71.75-58.6333.00-85.31-78.35-98.12-49.44116.00-45.4120.95-42.56-23.42-41.40-33.89-24.46NANANANANANANANANANANANANANA
Other Comprehensive Income Loss Net Of Tax -0.67-1.681.151.63-0.42-0.42-2.34-0.010.410.06-0.12-0.24-2.69-2.741.93-0.520.240.470.730.290.041.01-0.58-0.19-0.22-0.37-0.060.37-0.310.68-0.05-0.04-0.990.122.410.030.96-0.10-0.53
Net Income Loss -63.62-87.68-76.70-66.17-91.65-72.62-63.20-134.0849.80-133.99-71.75-58.6333.00-85.31-78.35-98.12-49.44116.00-45.4120.95-42.56-23.42-41.40-22.12-37.74-33.18-33.16-34.00-24.1524.32-27.84-51.37-45.1057.05-46.37-50.56-39.5346.83-16.24
Comprehensive Income Net Of Tax -64.29-89.36-75.56-64.55-92.07-73.05-65.55-134.0850.21-133.93-71.88-58.8830.31-88.06-76.42-98.65-49.20116.48-44.6821.24-42.52-22.41-41.97-22.31-37.96-33.55-33.22-33.63-24.4625.00-27.89-51.41-46.0957.17-43.96-50.53-38.5846.74-16.77

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Assets 460.43515.13538.54610.09608.84686.79745.93773.82850.51808.62787.30826.84812.01807.68824.38857.40893.96915.07812.40880.60855.64869.92867.61898.65894.89542.64441.76469.55486.21499.13442.54470.57499.25541.39435.54483.53NANANA
Liabilities 575.63575.43567.43611.57562.56563.04567.92544.71505.45528.77397.03385.39341.08392.54346.75321.99280.25266.76303.90352.13365.06355.12348.82316.20304.12293.27290.78294.44288.60286.75266.31273.75262.69268.51231.65242.85NANANA
Liabilities And Stockholders Equity 460.43515.13538.54610.09608.84686.79745.93773.82850.51808.62787.30826.84812.01807.68824.38857.40893.96915.07812.40880.60855.64869.92867.61898.65894.89542.64441.76469.55486.21499.13442.54470.57499.25541.39435.54483.53NANANA
Stockholders Equity -157.17-102.27-48.85-21.4526.31103.78158.05209.15325.79260.58371.00422.18451.66395.87458.36516.13594.45629.03489.22509.20471.31495.53499.52563.18571.50230.10131.70155.84178.34193.11156.95177.55217.28253.62184.62221.41NANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Assets Current 364.11411.36430.55492.83474.22520.64524.41474.06573.40564.47621.69755.11737.48727.17736.40702.49786.48805.79579.00690.01678.78720.08717.16748.97741.46371.34256.58266.52253.46252.31184.00200.56232.57263.58155.40198.24NANANA
Cash 70.9881.73145.81135.82104.51128.15165.44111.4290.90130.03100.7388.0580.55198.7149.4140.7290.7740.7872.2838.7871.5963.5269.56103.72104.88205.0286.6879.2492.6277.0996.2075.6995.49108.89119.11151.65NANANA
Cash And Cash Equivalents At Carrying Value 120.91152.59188.55155.70155.96167.76185.90171.22274.53353.36433.51678.39532.47429.27121.56126.27196.5974.5981.6789.26566.72643.80659.01673.66651.37290.28170.60173.78198.28190.41140.96153.32208.65236.54128.37165.46153.89182.6672.95
Short Term Investments 130.43183.13167.40266.31252.56270.38242.18233.97211.88153.85110.728.14155.40256.32413.87407.49432.04586.17483.73532.1486.01NANA62.06NANANANANANANANANANANANANANANA
Accounts Receivable Net Current 31.6925.6017.6516.3015.3333.5743.8817.4035.9924.2740.5441.8826.2526.5258.5428.4519.236.456.0263.6823.1930.199.978.458.638.937.2510.457.6918.095.9415.407.3712.186.9613.45NANANA
Inventory Net 40.7041.1842.4640.4439.9540.9043.0731.0229.3224.5320.7616.5311.808.588.416.894.911.98NA0.004.91NANANANANANANANANANANANANANANANANANA
Inventory Finished Goods 4.614.753.963.193.515.197.878.157.837.807.796.115.034.445.004.30NANANANANANANANANANANANANANANANANANANANANANANA
Other Assets Current NANANA4.35NANANA5.077.091.312.521.816.012.052.201.723.653.90NA2.22NANANANANANANANANANANANANANANANANANANA
Prepaid Expense And Other Assets Current 40.388.8614.4914.0810.438.049.3920.4521.698.4616.1610.1611.566.48134.03133.39133.72136.607.584.932.8718.003.424.802.863.015.912.893.963.714.653.993.682.735.754.97NANANA
Available For Sale Securities Debt Securities 130.43183.13167.40270.66270.34316.30335.67401.76NANANA8.39NANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Property Plant And Equipment Gross NANANA149.29NANANA149.28147.24147.03144.57144.89143.80141.21143.28143.11142.31140.79139.00192.40NANANA189.12NANANA177.30NANANA176.75NANANA174.49NANANA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment NANANA128.68NANANA121.01118.19116.36113.63111.25107.65104.22103.22100.3699.1095.9293.1865.20NANANA59.64NANANA53.64NANANA47.73NANANA42.32NANANA
Property Plant And Equipment Net 14.5116.8318.6920.6122.2924.5026.8828.2829.0530.6730.9333.6536.1536.9840.0642.7443.2144.8745.83127.20127.91128.83129.88129.48126.64122.59122.82123.66124.77126.26127.61129.02129.61130.45131.66132.17NANANA
Other Assets Noncurrent 3.954.354.675.284.944.506.935.925.114.629.133.434.036.868.609.377.074.814.193.423.175.244.884.523.813.282.982.151.991.761.662.021.841.801.711.60NANANA
Available For Sale Debt Securities Amortized Cost Basis 130.54183.61168.53273.19274.40320.37339.16402.66NANANA8.27NANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Liabilities Current 209.41194.07254.75273.56251.99240.34255.37225.50209.32232.76167.05163.19118.3577.5766.10102.7587.2982.8193.9289.03100.4390.5683.3477.2668.5059.7760.1165.1261.7466.4458.3067.1858.9963.5053.9662.75NANANA
Accounts Payable Current 19.2212.8071.2830.7619.3229.3636.3526.1023.8748.9924.0624.797.555.012.876.094.054.063.779.1410.133.223.555.516.413.262.956.222.043.471.546.524.233.922.434.55NANANA
Other Accrued Liabilities Current 6.978.637.506.864.706.995.494.895.755.038.938.099.347.715.074.545.226.075.435.549.638.767.556.4610.337.417.645.886.974.564.174.764.143.243.505.56NANANA
Accrued Liabilities Current 170.99162.77157.04219.77213.81193.10203.30172.59151.35147.80119.78119.5290.5750.4642.3183.8270.8366.5566.2866.1252.6049.4962.8663.7854.1248.5349.1850.9151.7547.9444.0447.9341.7746.2442.4748.98NANANA
Contract With Customer Liability Current 7.337.4916.5012.747.366.904.7415.8623.2625.2310.726.557.919.818.530.490.260.1412.1013.7737.7037.84NA16.67NANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Secured Long Term Debt 71.6771.41NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Minority Interest NANA19.9719.9719.9719.9719.9719.9719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.27NANANA
Other Liabilities Noncurrent 4.254.967.066.4414.3017.8324.3326.0224.3230.6638.3439.6437.64127.2489.1264.2736.0419.069.989.9910.299.328.568.056.696.255.846.194.764.995.244.610.750.700.700.70NANANA
Operating Lease Liability Noncurrent 70.0373.8176.8979.5981.0983.0885.9588.7891.4894.203.350.850.470.570.680.94NANANA0.00NANANANANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Stockholders Equity -157.17-102.27-48.85-21.4526.31103.78158.05209.15325.79260.58371.00422.18451.66395.87458.36516.13594.45629.03489.22509.20471.31495.53499.52563.18571.50230.10131.70155.84178.34193.11156.95177.55217.28253.62184.62221.41NANANA
Stockholders Equity Including Portion Attributable To Noncontrolling Interest -136.68-81.79-28.89-1.4846.27123.75178.01229.11345.06279.85390.27441.45470.93415.14477.63535.41613.72648.30508.49528.47490.58514.80518.79582.45590.77249.37150.97175.11197.62212.38176.22196.82236.56272.89203.89240.68NANANA
Common Stock Value 0.980.980.970.940.940.940.930.930.930.930.920.910.910.900.890.880.870.870.860.850.850.840.830.820.820.710.640.640.630.630.620.620.610.600.590.59NANANA
Additional Paid In Capital 1634.461625.071589.141541.021524.231509.641490.861476.411458.981443.971420.471399.771370.381344.911319.351300.721280.401265.781242.461226.451209.81NANA1160.09NANANANANANANA586.65574.98565.23553.41546.25NANANA
Retained Earnings Accumulated Deficit -1785.69-1722.07-1634.39-1557.69-1491.51-1399.86-1327.24-1264.03-1129.96-1179.75-1045.77-974.01-915.38-948.38-863.07-784.72-686.60-637.16-753.16-715.83-736.78-694.22-670.80-595.95-573.82-536.09-502.90-469.74-435.74-411.59-435.90-408.06-356.69-311.60-368.65-322.28NANANA
Accumulated Other Comprehensive Income Loss Net Of Tax -6.92-6.25-4.57-5.72-7.35-6.93-6.50-4.16-4.16-4.57-4.62-4.50-4.26-1.561.18-0.75-0.22-0.46-0.94-2.28-2.57-2.61-3.62-1.79-1.61-1.39-1.02-0.96-1.33-1.02-1.70-1.65-1.61-0.62-0.74-3.15NANANA
Minority Interest NANA19.9719.9719.9719.9719.9719.9719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.2719.27NANANA
Stock Issued During Period Value New Issues 0.0017.2831.13NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 9.4815.8816.1116.2115.5916.6617.1517.0715.7019.0019.3820.2717.8917.6416.9217.4014.7917.6416.4313.7114.3213.2310.88NANANANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Net Cash Provided By Used In Operating Activities -84.54-110.57-101.59-52.51-51.88-33.06-8.48-54.9644.26-26.54-44.98-7.23-1.35149.66-59.49-45.05-27.48-28.6522.48-17.468.25-34.96-31.96-1.19-18.43NANANANANANANANANANANANANANA
Net Cash Provided By Used In Investing Activities 54.22-14.29103.481.0944.7817.3025.93-50.57-122.15-57.53-196.72143.7798.86153.8556.01-25.03152.7718.77-26.49-462.86-89.2014.6415.3020.009.54NANANANANANANANANANANANANANA
Net Cash Provided By Used In Financing Activities -0.0291.5331.4848.67-1.092.09-2.89-0.03-0.832.38-2.085.664.224.65-1.19-0.28-3.242.75-3.532.823.925.092.043.41370.02NANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Net Cash Provided By Used In Operating Activities -84.54-110.57-101.59-52.51-51.88-33.06-8.48-54.9644.26-26.54-44.98-7.23-1.35149.66-59.49-45.05-27.48-28.6522.48-17.468.25-34.96-31.96-1.19-18.43NANANANANANANANANANANANANANA
Net Income Loss -63.62-87.68-76.70-66.17-91.65-72.62-63.20-134.0849.80-133.99-71.75-58.6333.00-85.31-78.35-98.12-49.44116.00-45.4120.95-42.56-23.42-41.40-22.12-37.74-33.18-33.16-34.00-24.1524.32-27.84-51.37-45.1057.05-46.37-50.56-39.5346.83-16.24
Profit Loss -63.62-87.68-76.70-66.17-91.65-72.62-63.20-134.0849.80-133.99-71.75-58.6333.00-85.31-78.35-98.12-49.44116.00-45.4120.95-42.56-23.42-41.40-33.89-24.46NANANANANANANANANANANANANANA
Increase Decrease In Accounts Receivable 6.288.711.300.22-17.18-10.2826.48-19.0511.74-16.53-1.3414.49-0.62-31.9930.099.2312.770.43-57.6640.50-7.0020.211.52-0.18-0.301.69-3.202.76-10.4012.15-9.478.03-4.815.22-6.49-7.975.26-4.983.65
Increase Decrease In Inventories -0.430.011.94-0.150.29-1.1412.001.504.803.574.293.973.190.491.521.982.931.980.000.000.00NANANANANANANANANANANANANANANANANANA
Increase Decrease In Accounts Payable 6.73-61.2640.4711.03-9.31-6.0110.211.92-0.10-0.34-0.6716.292.502.16-3.222.03-0.010.29-5.37-0.996.91-0.33-1.96-0.903.150.31-3.274.18-1.441.93-4.982.290.321.48-2.121.661.640.110.08
Share Based Compensation 9.4815.8816.1116.2215.5716.6617.1517.0715.7019.0019.3820.2717.8917.6416.9217.4014.7917.6416.4313.7114.3213.2310.889.939.639.578.417.888.518.407.347.456.846.946.458.968.270.670.80

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Net Cash Provided By Used In Investing Activities 54.22-14.29103.481.0944.7817.3025.93-50.57-122.15-57.53-196.72143.7798.86153.8556.01-25.03152.7718.77-26.49-462.86-89.2014.6415.3020.009.54NANANANANANANANANANANANANANA
Payments To Acquire Property Plant And Equipment 0.680.990.590.330.860.911.641.401.571.700.522.390.420.730.461.751.811.720.483.171.151.871.843.513.380.980.640.150.090.120.900.310.680.540.452.581.591.622.33

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Net Cash Provided By Used In Financing Activities -0.0291.5331.4848.67-1.092.09-2.89-0.03-0.832.38-2.085.664.224.65-1.19-0.28-3.242.75-3.532.823.925.092.043.41370.02NANANANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31
Revenues 40.1344.3236.1634.3715.7329.8160.8316.54155.9724.3638.4365.0044.0342.8924.407.9733.17191.5723.86108.0629.0343.9531.9342.5127.2729.0026.8931.9130.1089.2828.2824.4419.54120.5516.3016.1113.6689.9617.88
License And Development, Astellas, Collaborative Arrangement 2.40NANANA1.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Falikang, Collaborative Arrangement 26.5020.5021.4020.3014.9019.7016.203.1010.3011.8010.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 40.1344.3236.1634.3715.7329.8160.8316.54155.9724.3638.4365.0044.0342.8924.407.9733.17191.5723.86108.0629.0343.9531.9330.7440.5530.2726.8935.5230.1089.2828.2824.4419.54120.5516.3016.1113.6689.9617.88
Gross Accounts Receivable, Rebates And Discounts NANANA0.200.000.100.600.300.00NANA-9.304.20NANANANANANANANANANANANANANANANANANANANANANANANANANA
Development And Other Revenue 6.785.163.894.522.455.4611.769.9526.1019.6414.5921.5320.6618.9619.4528.6120.6640.9823.8635.3329.0329.6331.9330.7430.6230.27NANANANANANANANANANANANANA
Drug Product Revenue 1.3214.272.116.48-4.081.097.591.130.00-8.658.48-0.020.698.24NANANA0.00NANANANANANANANANANANANANANANANANANANANANA
License 2.651.006.000.000.000.0022.590.00116.43NANANANA0.000.0014.5711.94150.580.007.950.0014.320.000.009.93NANANANANANANANANANANANANANA
Product 29.3923.8924.1623.3717.3623.2618.885.4613.4413.3715.3629.1722.6815.694.96-35.200.580.000.0064.780.00NANANANANANANANANANANANANANANANANANA
Development And Other Revenue, License Agreement With Eluminex 0.240.250.230.260.460.280.76NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Other Revenue Patent Transfer, License Agreement With Eluminex 0.50NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
License, License Agreement With Eluminex 0.001.006.00NANA0.280.760.008.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Development And Other Revenue,, Astellas Collaboration Agreement 2.321.811.53NA1.371.755.151.5414.062.553.534.134.654.604.573.713.0016.854.614.124.665.004.724.554.80NANANANANANANANANANANANANANA
Development And Other Revenue,, Astellas Collaboration Agreement 0.040.030.100.130.040.080.030.000.070.100.080.810.090.160.160.070.540.370.250.340.471.140.450.460.520.32NANANANANANANANANANANANANA
Development And Other Revenue, United States Rest Of World And China, Astra Zeneca Agreements 3.682.272.032.770.583.355.828.4111.9716.9910.9817.9815.2213.7514.5624.7617.1123.7619.0030.8723.8923.4826.72NANANANANANANANANANANANANANANANA
License,, Astellas Collaboration Agreement NANANA0.000.000.0022.590.00108.43NANANANA0.000.000.000.00117.470.000.000.000.000.000.000.00NANANANANANANANANANANANANANA
License, United States Rest Of World And China, Astra Zeneca Agreements 2.65NANANANANANANANANANANANA0.000.0014.570.0033.110.007.950.000.000.00NANANANANANANANANANANANANANANANA
Product,, Astra Zeneca Agreements NANANANANA19.7016.203.1010.3011.8010.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product,, Direct Sales NANANANANA3.502.702.403.101.605.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product, Direct Sales 2.933.382.793.082.443.522.662.393.111.614.9629.1722.6815.694.96NANANANANANANANANANANANANANANANANANANANANANANANA
Product, Sales To Falikang 26.4620.5121.3720.2914.9119.7416.223.0710.3311.7610.41NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product, Direct Sales, Discounts And Rebates -0.26-0.23-0.27NA-0.17-0.01-0.17NA-0.13-0.62-0.56NA-5.21-4.09-0.42NANANANANANANANANANANANANANANANANANANANANANANANA
Product, Direct Sales, Sales Returns And Allowances 0.00-0.000.00-0.000.000.000.00-0.00-0.00-0.000.09-0.04-0.01-0.04NANANANANANANANANANANANANANANANANANANANANANANANANA
Product, Sales To Falikang, Increase Decrease In Deferred Revenue 2.30-3.332.113.09-4.621.522.35NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product, Sales To Falikang, Increase In Deferred Revenue NANANANA-4.62-1.52-2.35-9.13-8.76-5.38-3.93NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product, Sales To Falikang, Net Transfer Price 24.1623.8419.2617.2019.5318.2213.8812.2019.0917.1414.34NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product, Sales To Falikang, Profit Share -18.13-18.31-14.99-11.82-12.98-10.06-8.85-3.03-12.09-9.57-10.06NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
, A P I Shipment, Drug Product Revenue 0.700.60NANA4.30NA2.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
, Astellas Collaboration Agreement NANANANANA1.10NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
, Astellas Agreement, Drug Product Revenue 0.620.460.380.290.241.08NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
, Astellas Europe Agreement, Drug Product Revenue 4.707.4016.60NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
, Astellas Agreement, Drug Product Revenue 0.6913.811.736.184.310.027.590.000.00-1.97NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
, Astellas Collaboration Agreement, Drug Product Revenue NANANANANA0.007.600.002.10-2.004.00NANA8.20NANANANANANANANANANANANANANANANANANANANANANANANANA
, Drug Product Revenue NA14.401.708.40NANA9.80NANANANANANA8.20NANANANANANANANANANANANANANANANANANANANANANANANANA
A P I Shipment, Drug Product Revenue NANANANA-4.30NA2.200.000.002.004.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Astellas Agreement, Bulk Drug Product NANANANA7.70-2.2045.50NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Astellas Agreement, Development Revenue 2.401.801.60NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Astellas Agreement, Drug Product Revenue 1.3014.302.10NANANA7.591.130.00-1.974.030.00-3.968.24NANANANANANANANANANANANANANANANANANANANANANANANANA
Astra Zeneca Agreements, Bulk Drug Product 0.000.0011.200.000.000.0011.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Deferred For Future Recognition 2.303.302.10NA4.601.502.309.108.805.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Drug Product Revenue 1.3214.272.116.484.081.097.591.130.00-8.658.48-0.020.698.24NANANANANANANANANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Comprehensive Income Net Of Tax
Expenses
Income Tax Expense Benefit
Balance Sheet
Stockholders Equity
Assets
Property Plant And Equipment Net
Current Assets
Other Assets Current
NonCurrent Assets
Other Assets Noncurrent
PropertyPlantAndEquipmentNet
Property Plant And Equipment Net
Liabilities
Operating Lease Liability
Current Liabilities
Other Accrued Liabilities Current
Noncurrent Liabilities
Other Liabilities Noncurrent
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
Shares
Weighted Average Number Of Share Outstanding Basic And Diluted
OperatingLeaseLiability
Operating Lease Liability Current
NonoperatingIncomeExpense
Nonoperating Income Expense
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Undiscounted Excess Amount
InventoryNet
Inventory Finished Goods

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:TypeOfArrangement
('us-gaap:Product', 'CN', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('us-gaap:Product', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ValuationAllowancesAndReservesType
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:StatementGeographical, us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('JP', None, 'fgen:DrugProductRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Statement Geographical, us-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('fgen:AstellasAgreement', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('us-gaap:Product', 'fgen:SalesToFalikang', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('us-gaap:Product', 'fgen:DirectSales', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
(None, 'fgen:LicenseAgreementWithEluminex')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType
('us-gaap:FairValueInputsLevel2', 'us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Fair Value Hierarchy Level, us-gaap: Fair Value By Measurement Frequency, us-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByMeasurementFrequency, us-gaap:InvestmentType
('us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Measurement Frequency, us-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:InvestmentType
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueInputsLevel2', 'us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Fair Value Hierarchy Level, us-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)
Property Plant And Equipment Grossus-gaap: Property Plant And Equipment By Type
us-gaap:PropertyPlantAndEquipmentNet
us-gaap:StatementGeographical
(None,)
Property Plant And Equipment Netus-gaap: Statement Geographical
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:InvestmentType
(None,)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Investment Type
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument
(None,)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Financial Instrument
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents
(None,)
Stockholders Equity Including Portion Attributable To Noncontrolling Interestus-gaap: Statement Equity Components
us-gaap:StockIssuedDuringPeriodValueNewIssues
us-gaap:StatementEquityComponents
(None,)
Stock Issued During Period Value New Issuesus-gaap: Statement Equity Components
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:TypeOfArrangement
('us-gaap:Product', 'CN', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
('us-gaap:Product', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ValuationAllowancesAndReservesType
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:StatementGeographical, us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('JP', None, 'fgen:DrugProductRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Statement Geographical, us-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('fgen:AstellasAgreement', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('us-gaap:Product', 'fgen:SalesToFalikang', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement, us-gaap:ValuationAllowancesAndReservesType
('us-gaap:Product', 'fgen:DirectSales', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement, us-gaap: Valuation Allowances And Reserves Type
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByType
(None, 'fgen:LicenseAgreementWithEluminex')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Research And Development Arrangement Contract To Perform For Others By Type